全文获取类型
收费全文 | 1349篇 |
免费 | 98篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 62篇 |
妇产科学 | 14篇 |
基础医学 | 133篇 |
口腔科学 | 33篇 |
临床医学 | 192篇 |
内科学 | 290篇 |
皮肤病学 | 21篇 |
神经病学 | 65篇 |
特种医学 | 266篇 |
外科学 | 134篇 |
综合类 | 22篇 |
预防医学 | 75篇 |
眼科学 | 8篇 |
药学 | 64篇 |
中国医学 | 5篇 |
肿瘤学 | 65篇 |
出版年
2023年 | 8篇 |
2022年 | 5篇 |
2021年 | 32篇 |
2020年 | 11篇 |
2019年 | 16篇 |
2018年 | 38篇 |
2017年 | 20篇 |
2016年 | 23篇 |
2015年 | 33篇 |
2014年 | 33篇 |
2013年 | 40篇 |
2012年 | 36篇 |
2011年 | 39篇 |
2010年 | 53篇 |
2009年 | 62篇 |
2008年 | 47篇 |
2007年 | 33篇 |
2006年 | 39篇 |
2005年 | 19篇 |
2004年 | 19篇 |
2003年 | 22篇 |
2002年 | 24篇 |
2001年 | 23篇 |
2000年 | 17篇 |
1999年 | 19篇 |
1998年 | 59篇 |
1997年 | 55篇 |
1996年 | 69篇 |
1995年 | 53篇 |
1994年 | 46篇 |
1993年 | 51篇 |
1992年 | 21篇 |
1991年 | 16篇 |
1990年 | 29篇 |
1989年 | 47篇 |
1988年 | 41篇 |
1987年 | 35篇 |
1986年 | 42篇 |
1985年 | 29篇 |
1984年 | 23篇 |
1983年 | 13篇 |
1982年 | 26篇 |
1981年 | 15篇 |
1980年 | 8篇 |
1979年 | 7篇 |
1978年 | 7篇 |
1977年 | 13篇 |
1976年 | 12篇 |
1975年 | 14篇 |
1966年 | 2篇 |
排序方式: 共有1454条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
3.
4.
5.
6.
7.
8.
9.
V. van Casteren P. Leurquin A. Bartelds F. Gurtner V. Massari S. Maurice-Tison A.T. Vega R. Mak 《European journal of epidemiology》1993,9(2):169-175
This study describes a p. year international data collection on the demand pattern for HIV-antibody tests in general practice recorded by 6 sentinel networks in 5 European countries. The purpose of the recording was to evaluate the use of HIV-antibody testing by general practitioners and the demand for testing among the general population. Sentinel networks of general practitioners are a possible and available instrument for monitoring the perception of the HIV-test, and indirectly of the threat of the HIV-epidemic by the public and by the general practitioners (GPs). Differences were found between the countries in the frequency of testing, the person asking the test and the reason for testing. Possible explanatory factors, such as differences in the routine testing of specific groups, differences in the training and in the role of the GP, differences in the characteristics of prevention policy, are discussed. The European comparison also offers the opportunity to reflect on common medical practice in dealing with demands for HIV-tests. 相似文献
10.